Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Moderate Buy" by Analysts
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat reports...